Ignite Creation Date:
2024-05-05 @ 11:21 AM
Last Modification Date:
2024-10-26 @ 9:02 AM
Study NCT ID:
NCT00001242
Status:
COMPLETED
Last Update Posted:
2023-01-20
First Post:
1999-11-03
Brief Title:
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases NIDDK
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Studies of States With Resistance to Vitamin D and Parathyroid Hormone
Status:
COMPLETED
Status Verified Date:
2023-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone PTH will be admitted for diagnosis treatment review with suggestions for modifications to the current or new treatment and for inclusion in other protocols These states include hypocalcemia rickets osteomalacia pseudohypoparathyroidism Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor in blood Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder The principal therapies will be combinations of calcium phosphate and a vitamin D analog Selected patients will have localization and surgery to remove a tumor that causes renal wasting of phosphate Patients will also be considered for entry into other research protocols
Detailed Description:
Patients with confirmed or suspected states with resistance to vitamin D or parathyroid hormone PTH will be admitted for diagnosis treatment review with suggestions for modifications to the current or new treatment and for inclusion in other protocols These states include hypocalcemia rickets osteomalacia pseudohypoparathyroidism Resistance to a factor is manifested by deficient bioeffect despite high levels of the factor in blood Patients will be tested with multiple indices of mineral metabolism to establish the diagnosis and examine the spectrum of the underlying disorder The principal therapies will be combinations of calcium phosphate and a vitamin D analog Selected patients will have localization and surgery to remove a tumor that causes renal wasting of phosphate Patients will also be considered for entry into other research protocols
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 89-DK-0173 | None | None | None |